Lawler Patrick R, Akinkuolie Akintunde O, Ridker Paul M, Sniderman Allan D, Buring Julie E, Glynn Robert J, Chasman Daniel I, Mora Samia
Center for Lipid Metabolomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Clin Chem. 2017 Apr;63(4):870-879. doi: 10.1373/clinchem.2016.264515. Epub 2017 Feb 7.
It is uncertain whether measurement of circulating total atherogenic lipoprotein particle cholesterol mass [non-HDL cholesterol (nonHDLc)] or particle concentration [apolipoprotein B (apo B) and LDL particle concentration (LDLp)] more accurately reflects risk of incident coronary heart disease (CHD). We evaluated CHD risk among women in whom these markers where discordant.
Among 27533 initially healthy women in the Women's Health Study (NCT00000479), using residuals from linear regression models, we compared risk among women with higher or lower observed particle concentration relative to nonHDLc (highest and lowest residual quartiles, respectively) to individuals with agreement between markers (middle quartiles) using Cox proportional hazards models.
Although all 3 biomarkers were correlated ( ≥ 0.77), discordance occurred in up to 20.2% of women. Women with discordant high particle concentration were more likely to have metabolic syndrome (MetS) and diabetes (both < 0.001). Over a median follow-up of 20.4 years, 1246 CHD events occurred (514725 person-years). Women with high particle concentration relative to nonHDLc had increased CHD risk: age-adjusted hazard ratio (95% CI) = 1.77 (1.56-2.00) for apo B and 1.70 (1.50-1.92) for LDLp. After adjustment for clinical risk factors including MetS, these risks attenuated to 1.22 (1.07-1.39) for apo B and 1.13 (0.99-1.29) for LDLp. Discordant low apo B or LDLp relative to nonHDLc was not associated with lower risk.
Discordance between atherogenic particle cholesterol mass and particle concentration occurs in a sizeable proportion of apparently healthy women and should be suspected clinically among women with cardiometabolic traits. In such women, direct measurement of lipoprotein particle concentration might better inform CHD risk assessment.
循环中致动脉粥样硬化脂蛋白颗粒胆固醇质量[非高密度脂蛋白胆固醇(nonHDLc)]或颗粒浓度[载脂蛋白B(apo B)和低密度脂蛋白颗粒浓度(LDLp)]的测量,哪一个能更准确地反映冠心病(CHD)发病风险尚不确定。我们评估了这些指标不一致的女性患冠心病的风险。
在女性健康研究(NCT00000479)中27533名最初健康的女性中,利用线性回归模型的残差,我们使用Cox比例风险模型,比较了颗粒浓度相对于nonHDLc较高或较低的女性(分别为最高和最低残差四分位数)与指标一致的个体(中间四分位数)的风险。
尽管所有3种生物标志物都具有相关性(≥0.77),但高达20.2%的女性出现了不一致情况。颗粒浓度高且不一致的女性更易患代谢综合征(MetS)和糖尿病(P均<0.001)。在中位随访20.4年期间,发生了1246例冠心病事件(514725人年)。颗粒浓度相对于nonHDLc较高的女性冠心病风险增加:apo B的年龄调整风险比(95%CI)=1.77(1.56 - 2.00),LDLp为1.70(1.50 - 1.92)。在调整包括MetS在内的临床风险因素后,这些风险分别降至apo B为1.22(1.07 - 1.39),LDLp为1.13(0.99 - 1.29)。相对于nonHDLc,apo B或LDLp低且不一致与较低风险无关。
在相当比例的表面健康女性中,致动脉粥样硬化颗粒胆固醇质量与颗粒浓度之间存在不一致,对于有心脏代谢特征的女性临床应予以怀疑。在此类女性中,直接测量脂蛋白颗粒浓度可能会更好地指导冠心病风险评估。